Sickle cell, anemia and red cell disorders at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
76 organizations at ASH 2026 present work in sickle cell, anemia & red cell disorders: 26 hospitals and cancer centres, 22 universities and research institutes, 17 government and non-profit bodies, 8 pharma and biotech companies and 3 suppliers and service providers. Between them they bring 104 presentations to the program. Most represented: Mayo Clinic (11 on the program), Stanford University (10 on the program), University of Pennsylvania (9 on the program). 54 of them have their own page in this guide. As of Sep 27, 2026.
Format
Top represented
Showing 1–3 of 76 organizations
| Organization | ASH 2026 Attendance |
|---|---|
Mayo Clinic Rochester, MN | |
Non-profit academic medical center with main campuses in Minnesota, Arizona and Florida, providing patient care, research and education. | Symposium Fri Dec 11 11:00am–2:00pm Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together Diagnosing light-chain amyloidosis earlier, personalizing treatment including fibril-targeting drugs, supporting patients, and improving team workflows. Symposium Fri Dec 11 7:00am–10:00am Anti-BCMA Bispecific Antibodies in Multiple Myeloma: From Biology to Real-World Implementation Bispecific antibodies targeting B-cell maturation antigen in myeloma, from mechanism and resistance to trial data, outpatient dosing, and infection prevention. Symposium Fri Dec 11 11:00am–2:00pm Transforming Care for Newly-Diagnosed Multiple Myeloma: Integrating Evidence-Based Innovation into Community Practice Newly diagnosed multiple myeloma care in community clinics, using frailty assessment, dose adjustment to protect quality of life, and new drug formulations. Talk Running on Wheels: How Mouse Models Inform the Study of Plasma Cell Biology Immune-competent mouse models of multiple myeloma that mimic its interplay with bone marrow, used to test new immune and cell therapies before trials. Talk Clonal Dominance in VEXAS An adult-onset inflammatory blood disorder caused by mutation of one protein-tagging enzyme, and how extra mutations shape inflammation and treatment. Session Don't Miss It! Methemoglobinemia: Inherited and Acquired How to evaluate unexplained cyanosis, recognize inherited or acquired methemoglobinemia with lab tests, and manage it without costly unnecessary workups. Talk Laboratory Testing in Methemoglobinemia Lab diagnosis of methemoglobinemia and sulfhemoglobinemia, where altered hemoglobin carries oxygen poorly, and test pitfalls in inherited versus acquired cases. Talk Older Adults Take the Lead: Revolutionizing B-cell ALL Treatment with Chemo-Sparing Approaches Chemotherapy-light care of older adults with B-cell acute lymphoblastic leukemia, using fitness and residual disease to sequence immunotherapies and transplant. Talk Session Treating Fairly Rounds Lunch How hematologists and fellows can influence healthcare reform on research funding, Medicaid, and hospital budgets, and how policy shapes health inequities. |
Stanford University Stanford, CA | |
Private research university in Stanford, California, including its School of Medicine. | Symposium Fri Dec 11 7:00am–10:00am A Hematologist’s Guide to the Sickle Cell Disease Revolution: Genes, Activators, and Beyond Approved and emerging gene therapies and new pyruvate kinase activators for sickle cell disease, and how to match patients to each and refer them. Session AI Models of Cell State for the Design of Next-Generation T Cell Therapies Using AI trained on patient data to predict which T cell states make CAR-T therapy work, moving cell design beyond trial and error. Talk Clinically Informed AI Models for Predicting and Engineering CAR T Cell Function Predicting which lymphoma patients respond to CAR-T from single-cell RNA profiles of the infused cells, then simulating better designs on a computer. Talk New Standards in GVHD Prophylaxis: Towards a Future Without GVHD Newer ways to prevent graft-versus-host disease after donor transplants, such as engineered cell grafts, abatacept, and post-transplant cyclophosphamide. Talk Clonal Hematopoiesis of Indeterminate Potential and Arterial Thrombosis: Mechanisms and Clinical Implications How clonal hematopoiesis alters myeloid cells to promote atherosclerosis, and how to evaluate affected patients for heart attack and stroke risk. Session From Mutations to Manifestations: Connecting Clonal Hematopoiesis (CH) and Thrombosis How clonal hematopoiesis, the age-related spread of mutated blood cells, fuels inflammation and artery and vein clots, and whether anti-inflammatory drugs help. Talk Targeted Therapies: From Genomic Insights to Therapeutic Strategies Genomic insights behind three targeted drug classes for childhood acute myeloid leukemia: blockers of B-cell lymphoma 2, menin and fms-like tyrosine kinase 3. Talk Treatment Sequencing After CAR-T Failure in Multiple Myeloma Choosing the next treatment for multiple myeloma that relapses after CAR-T cell therapy, weighing key clinical factors and approved and emerging options. Session Showcasing a Decade of Discoveries in Blood Advances Ten years of the hematology journal Blood Advances, revisiting its most influential clinical trials, basic science studies and practice guidelines. Talk Limitations and Risks of Generative AI Where generative AI fails in medicine, from hallucinations and bias to rare-disease blind spots, and how validation, governance, and human oversight reduce harm. Session Session Session Session |
University of Pennsylvania Philadelphia, PA | |
Private research university in Philadelphia, home to the Perelman School of Medicine. | Symposium Fri Dec 11 7:00am–10:00am B-Cell–Directed Therapies in Immune Thrombocytopenia: Real-World Practice Newer B-cell-targeting treatments for immune thrombocytopenia and how to fit them into care to achieve lasting platelet responses. Symposium Fri Dec 11 3:00pm–6:00pm Evidence at Every Step: Applying the Latest CAR T-Cell Data Across the NHL Care Continuum Getting relapsed lymphoma patients to CAR-T sooner, with earlier referral, bridging therapy, sequencing choices, and management of immune and nerve toxicities. Talk Rational Design of FVIII Variants for Gene Therapy: Linking Molecular Insight to Therapeutic Performance Engineering a better version of the clotting protein missing in hemophilia A for gene therapy, balancing stronger bleeding control against clot risk. Session JOINT SESSION - New Horizons in RNA Biology in Myeloid Development and Malignancy Every stage of the RNA life cycle, from splicing to chemical marks, shapes blood stem cells and blood cancers, pointing to new treatments. Talk Beyond Remission: Long-Term Hematopoietic Toxicity and Second Malignancies After CAR-T Cell Therapy Persistently low blood counts and second cancers after CAR-T therapy, including their frequency, causes, and how to monitor, prevent, and manage them. Talk Flt3 inhibitors in newly diagnosed and relapsed patients Evidence behind current Flt3 inhibitor use in newly diagnosed and relapsed acute myeloid leukemia, and where investigational approaches are heading. Talk Indications and Timing of Splenectomy in Hereditary Hemolytic Anemia When and how to remove the spleen in inherited red cell membrane and enzyme disorders, weighing benefit against lifelong infection and clotting risks. Session |
Instantly find 20 buyers in sickle cell, anemia & red cell disorders
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Browse ASH 2026 by
Organization type
Topic
- Leukemias, MDS & MPN 110
- Lymphoma & CLL 81
- Myeloma & Amyloidosis 74
- Bispecifics, ADCs & Targeted Drugs 92
- Transplant, Cell & Gene Therapy 86
- Sickle Cell, Anemia & Red Cell Disorders 76
- Bleeding, Clotting & Platelets 53
- Stem Cells & Blood Biology 52
- AI, Genomics & Data 42
- Clinical Practice & Access to Care 87
Exhibit hall
Everyone
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction